The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment

Pierre Poitras, Marie-Hélène Gingras, Jens F Rehfeld

52 Citationer (Scopus)

Abstract

Patients with Zollinger-Ellison syndrome (ZES) are treated by proton pump inhibitors (PPIs) to protect them from severe and potentially lethal peptic complications related to massive gastric acid hypersecretion. We report here on the dangerous consequences of interrupting PPI therapy.
OriginalsprogEngelsk
TidsskriftClinical Gastroenterology and Hepatology
Vol/bind10
Udgave nummer2
Sider (fra-til)199-202
Antal sider4
ISSN1542-3565
DOI
StatusUdgivet - 2012

Fingeraftryk

Dyk ned i forskningsemnerne om 'The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment'. Sammen danner de et unikt fingeraftryk.

Citationsformater